Latest Conference Articles

January 29th 2021, 4:45pm

IASLC World Conference on Lung Cancer

January 29, 2021 - Amivantamab elicited high and sustained responses in pretreated patients with non–small cell lung cancer harboring EGFR exon 20 insertion mutations.

January 29th 2021, 4:22pm

IASLC World Conference on Lung Cancer

January 29, 2021 - The first-in-class oral kinase inhibitor bemcentinib, when used in combination with pembrolizumab, demonstrated clinical activity with favorable tolerability in patients with checkpoint inhibitor–naïve and CPI-refractory composite AXL–positive non–small cell lung cancer.

January 29th 2021, 3:12pm

IASLC World Conference on Lung Cancer

Joshua K. Sabari, MD, discusses updated results from the phase 1 CHRYSALIS trial examining amivantamab in patients with non–small cell lung cancer whose tumors harbored EGFR exon 19 deletion or L858R mutations.

January 29th 2021, 12:47am

IASLC World Conference on Lung Cancer

January 28, 2021 - Treatment with the KRAS G12C inhibitor sotorasib (formerly AMG 510) elicited a 6.8-month median progression-free survival in patients with KRAS G12C–mutated advanced non–small cell lung cancer.

January 28th 2021, 10:51pm

IASLC World Conference on Lung Cancer

January 28, 2021 - Treatment with liposomal irinotecan demonstrated promising anti-tumor activity and safety in patients with small cell lung cancer who progressed on platinum-based treatment in the firstline setting.

January 28th 2021, 10:38pm

IASLC World Conference on Lung Cancer

January 28, 2021 - The NeoADAURA trial will evaluate the safety and efficacy of neoadjuvant osimertinib, as a single agent or in combination with platinum-based chemotherapy compared with chemotherapy alone, in patients with resectable, stage II-IIIB non–small cell lung cancer whose tumors harbor EGFR mutations.

January 28th 2021, 10:12pm

IASLC World Conference on Lung Cancer

January 28, 2021- Patients with non-small cell lung cancer who experience immune-related adverse events may have better survival outcomes than those without.

January 28th 2021, 10:08pm

IASLC World Conference on Lung Cancer

January 28, 2021 - The combination of osimertinib and savolitinib may be able to overcome MET resistance in patients with EGFR-mutant, MET-amplified or -overexpressed non–small cell lung cancer, including those who have previously progressed on a prior EGFR TKI.

January 28th 2021, 10:00pm

IASLC World Conference on Lung Cancer

January 28, 2021 - Atezolizumab demonstrated continued clinically meaningful benefits in overall survival, progression-free survival, overall response rate, and duration of response compared with chemotherapy in patients with PD-L1–high wild-type nonsquamous or squamous non–small cell lung cancer.

January 28th 2021, 9:50pm

IASLC World Conference on Lung Cancer

January 28, 2021 - Adding BMS-986012, anti–fucosyl-GM1 monoclonal antibody, to nivolumab demonstrated promising results in the treatment of patients with relapsed/refractory small cell lung cancer who did not receive previous checkpoint inhibitor therapy.

January 28th 2021, 8:52pm

IASLC World Conference on Lung Cancer

January 28, 2021 - Rapid, high, and uniform brain exposure was seen with [11C]osimertinib, followed by a reduction in total brain metastases volume with oral administration of the EGFR TKI in patients with EGFR-mutant non–small cell lung cancer and brain metastases.

January 28th 2021, 8:46pm

IASLC World Conference on Lung Cancer

January 28, 2021 - NRG1 fusions are detectable in patients with non–small cell lung cancer, providing a rationale to perform larger, retrospective studies assessing therapeutic outcomes in patients with NRG1 fusion–positive tumors and evaluate afatinib in this patient subgroup.

January 28th 2021, 8:44pm

IASLC World Conference on Lung Cancer

January 28, 2021 - Immuno-oncology therapies provided significant potential health gains for both patients and the population, although age should be taken into account to improve accuracy and avoid bias.

January 28th 2021, 7:53pm

IASLC World Conference on Lung Cancer

January 28, 2021 — Frontline pembrolizumab continued to demonstrate clinically meaningful improvements in overall survival, overall response rate, and time to progression on next-line therapy compared with platinum-based chemotherapy in patients with locally advanced or metastatic PD-L1–positive non–small cell lung cancer without sensitizing EGFR or ALK mutations.

January 28th 2021, 6:28pm

World Conference on Lung Cancer

January 28, 2021 - Pembrolizumab continued to demonstrate a clinically meaningful improvement in overall and progression-free survival, compared with docetaxel, in patients with previously treated, PD-L1–positive advanced non-small cell lung cancer after more than 5 years of follow-up.

January 28th 2021, 5:44pm

World Conference on Lung Cancer

January 28, 2021 - The addition of apatinib to single agent chemotherapy showed promising efficacy and was found to be well tolerated in patients with pretreated advanced small cell lung cancer.

January 28th 2021, 5:40pm

IASLC World Conference on Lung Cancer

January 28, 2021 - Although survivors and patients with lung cancer felt that they were involved in the treatment decision-making process, nearly half of them reported that they knew what their treatment options were before making a decision.

January 28th 2021, 5:31pm

IASLC World Conference on Lung Cancer

January 28, 2021 — Pembrolizumab in combination with chemotherapy continued to show improved overall survival and progression-free survival compared with chemotherapy alone in patients with previously untreated metastatic nonsquamous non–small cell lung cancer.

January 18th 2021, 4:27pm

Gastrointestinal Cancers Symposium (ASCO GI)

Single-agent pembrolizumab demonstrated durable antitumor activity among patients with treatment-naïve hepatocellular carcinoma, suggesting that the checkpoint inhibitor may have additional utility in this space, according to findings from a phase 2 trial presented during the 2021 Gastrointestinal Cancers Symposium.

January 18th 2021, 12:05am

Gastrointestinal Cancers Symposium (ASCO GI)

January 17, 2021 - Pembrolizumab demonstrated maintained numerical improvements in overall survival and progression-free survival compared with placebo in patients with previously treated advanced hepatocellular carcinoma.